Ethinylestradiol/drospirenone

Ethinylestradiol/drospirenone
	Ethinylestradiol
	Drospirenone
Combination of
Ethinylestradiol	Estrogen
Drospirenone	Progestogen; Progestin; Antimineralocorticoid; Antiandrogen
Clinical data
Trade names	With 30 μg ethinylestradiol: Yasmin, others; With 20 μg ethinylestradiol: Yaz, Yasminelle, others
Other names	EE/DRSP
AHFS/Drugs.com	Professional Drug Facts
MedlinePlus	a601050
License data	US DailyMed: Drospirenone_and_estradiol;
Pregnancy; category	AU: B3[1];
Routes of; administration	By mouth
Drug class	Estrogen; Progestin; Progestogen; Antimineralocorticoid; Antiandrogen
ATC code	G03FA17 (WHO) ;
Legal status
Legal status	US: ℞-only ;
Identifiers
CAS Number	164017-31-6;
KEGG	D09741;

Ethinylestradiol/drospirenone (EE/DRSP), sold under the brand name Yasmin among others, is a combination of ethinylestradiol (EE), an estrogen, and drospirenone (DRSP), a progestin, antimineralocorticoid, and antiandrogen, which is used as a birth control pill to prevent pregnancy in women.[2][3][4][5][6] It is also indicated for the treatment of moderate acne, premenstrual syndrome (PMS), premenstrual dysphoric disorder (PMDD), and dysmenorrhea (painful menstruation) in women.[3] The medication is taken by mouth and contains 30 μg EE and 3 mg DRSP per tablet (brand names Yasmin, others) or 20 μg EE and 3 mg DRSP per tablet (brand names Yaz, Yasminelle, Nikki, others).[4][5] A formulation with levomefolic acid (vitamin B₉) has also been marketed (brand names Beyaz, Safyral, others), with similar indications.[7][8] EE/DRSP is marketed widely throughout the world.[9]

In 2020, it was the 145th most commonly prescribed medication in the United States, with more than 4 million prescriptions.[10][11]

References

"Drospirenone / estradiol (Angeliq) Use During Pregnancy". Drugs.com. 6 September 2018. Retrieved 18 March 2020.
"Ethinylestradiol/Drospirenone". AdisInsight. Springer Nature Switzerland AG.
"Drospirenone/Ethinylestradiol low-dose - Bayer HealthCare Pharmaceuticals". AdisInsight. Springer Nature Switzerland AG.
Bayer HealthCare Pharmaceuticals Inc. "Highlights of Prescribing Information: Yasmin" (PDF). U.S. Food and Drug Administration.
Bayer HealthCare Pharmaceuticals Inc. "Highlights of Prescribing Information: Yaz" (PDF). U.S. Food and Drug Administration. Retrieved 31 October 2017.
Keam SJ, Wagstaff AJ (2003). "Ethinylestradiol/drospirenone: a review of its use as an oral contraceptive". Treatments in Endocrinology. 2 (1): 49–70. doi:10.2165/00024677-200302010-00005. PMID 15871554. S2CID 209144694.
"Ethinylestradiol/Drospirenone/Folic acid". AdisInsight. Springer Nature Switzerland AG.
Bayer HealthCare Pharmaceuticals Inc. "Highlights of Prescribing Information: Beyaz" (PDF). U.S. Food and Drug Administration.
"Drospirenone Uses, Side Effects & Warnings". Drugs.com.
"The Top 300 of 2020". ClinCalc. Retrieved 7 October 2022.
"Drospirenone; Ethinyl Estradiol - Drug Usage Statistics". ClinCalc. Retrieved 7 October 2022g.

"Drospirenone mixture with estradiol". Drug Information Portal. U.S. National Library of Medicine.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.